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Norovirus GII.4 is a major cause of global outbreaks of viral gastroenteritis in humans,
and has evolved by antigenic changes under the constantly changing human herd
immunity. Major shift in the pandemic GII.4 strain periodically occurs concomitant with
changes in the antigenic capsid protein VP1. However, how the newly emerged strain
evolves after the onset of pandemic remains unclear. To address this issue, we examined
molecular evolution of a pandemic lineage, termed the GII.4_2006b, by using the
full-length viral genome and VP1 sequences (n = 317) from stools collected at 20 sites
in Japan between 2006 and 2011. Phylogenetic tree showed a radial diversification
of the genome sequences of GII.4_2006b, suggesting a rapid genetic diversification
of the GII.4_2006b population from a few ancestral variants. Impressively, amino acid
sequences of the variable VP1 in given seasons remained as homogeneous as those
of viral enzymes under annual increase in the nucleotide diversity in the VP1 coding
region. The Hamming distances between the earliest and subsequent variants indicate
strong constraints on amino acid changes even for the highly variable P2 subdomain.
These results show the presence of evolutionary constraints on the VP1 protein and viral
enzymes, and suggest that these proteins gain near maximal levels of fitness benefits
in humans around the onset of the outbreaks. These findings have implications for our
understanding of molecular evolution, mechanisms of the periodic shifts in the pandemic
NoV GII.4 strains, and control of the NoV GII.4 pandemic strain.
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INTRODUCTION
Norovirus (NoV) is a non-enveloped RNA virus that belongs to the family Caliciviridae. NoV is
divided into multiple genogroups, which are further subgrouped into more than 40 genotypes
(Zheng et al., 2006; Donaldson et al., 2010; Robilotti et al., 2015). Among them, genogroup
II genotype 4 (GII.4) is especially important in public health, because it is the leading cause
of NoV-associated acute gastroenteritis in humans (Noel et al., 1999; Siebenga et al., 2007;
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Zheng et al., 2010). NoV is highly variable, and emergence of
a novel GII.4 variant is in some cases associated with global
outbreaks of gastroenteritis (Lopman et al., 2004; Vipond et al.,
2004; Reuter et al., 2005; Bull et al., 2006; Gallimore et al., 2007;
Motomura et al., 2008). A major shift in the pandemic strain
occurs with antigenic mutations (Lindesmith et al., 2008, 2011,
2012a, 2013) and viral genome recombination at the ORF1/2
boundary region (Motomura et al., 2010; Eden et al., 2013).
The VP1 protein is the major structural protein of the
mature virion, which protrudes from the virion surface and
plays pivotal roles in the viral interactions with hosts. The VP1
protein is composed of two domains, protruding (P) and shell (S)
(Prasad et al., 1999). The P domain is further divided into two
subdomains, P1 and P2 (Prasad et al., 1999). The P2 subdomain
is placed on the tip of the VP1 protein and constitutes the major
antigenic site around the binding site to the putative receptor(s)
for infection (Donaldson et al., 2010). This structural feature
causes sequence variation (Lindesmith et al., 2008, 2011, 2012a,
2013; Bok et al., 2009; Debbink et al., 2012) and structural
diversity (Chen et al., 2004, 2006; Donaldson et al., 2010),
particularly in the P2 subdomain. Meanwhile, the functional
importance of the P2 subdomain can cause suppression of
deleterious changes and/or changes that reduce viral replication
fitness. However, very little is known about evolution of the VP1
protein during viral maintenance in human populations.
To address this issue, we examined here molecular evolution
of the VP1 protein of a pandemic lineage, termed GII.4_2006b,
which is also known as the GII.4 Den Haag 2006b. In the
autumn/winter of 2006, the national epidemiological surveillance
of infectious diseases in Japan reported an unusual increase
in the number of outbreaks of NoV infections (Infectious
Disease Surveillance Center1). This augmentation was associated
with the nationwide spread of a newly emerging GII.4 variant
(Motomura et al., 2008), termed GII.4_2006b. The GII.4_2006b
initially coexisted as a minority strain among various other NoV
lineages in Japan, but starting in October of 2006 it spread
extremely rapidly and remained as the major epidemic variant
across Japan between 2006 and 2009 (Motomura et al., 2008,
2010). In this study, we characterized nucleotide and amino
acid diversities of the VP1 proteins, using serially collected
full-length 317 NoV genome and VP1 sequences from infections
in Japan between 2006 and 2011. The obtained results show
long-term persistent of GII.4_2006b in human populations
in Japan as a dominant GII.4 subpopulation. Interestingly,
both the VP1 protein and viral enzymes had remained as
highly homogeneous populations, indicating strong evolutionary
constraints on changes in these proteins following the onset of
the outbreaks.
MATERIALS AND METHODS
NoV Genome Sequencing
Stool specimens were collected from individuals with acute
gastroenteritis at 20 regional public health institutes in Japan
1http://idsc.nih.go.jp/iasr/prompt/graph-ke.html
between May 2006 and March 2011 in compliance with the
Food Sanitation Law of Japan, according to the methods for
the protection of personal information (including methods for
anonymization in an unlinkable fashion). The research was
approved by research and ethical committee in National Institute
of Infectious Diseases. Three to five stool specimens were
collected at each site in each year. NoV genome sequences
were obtained from the stool specimens as described previously
(Motomura et al., 2008, 2010).
Genotype Determination
Norovirus genotype was determined by construction of
phylogenetic trees of viral genome sequences. Multiple sequence
alignments were done as described previously (Motomura
et al., 2008, 2010) using the MAFFT (Katoh et al., 2009) and
alignment tools implemented in the MEGA software suite
(Tamura et al., 2011). Phylogenetic trees were constructed as
described previously (Motomura et al., 2008, 2010) using MEGA
software (Tamura et al., 2011). The reliability of interior branches
in the tree was assessed by the bootstrap method with 1,000
resamplings.
Analysis of Diversity of Sequence
Population
Mean diversity in the entire sequence population was computed
with the “Sequence Diversity” menu in MEGA software suite
(Tamura et al., 2011). The overall pairwise mean distance
between the sequences was computed with the “Distances”
menu in MEGA. As substitution models, a maximum composite
likelihood and a Poisson model were used for nucleotide and
amino acid sequences, respectively. Variance was estimated by the
bootstrap method with 100 to 500 bootstrap replications.
Analysis of Individual Amino Acid
Variation
Amino acid variations at each position of the VP1 (1–530)
were calculated as previously described with a multiple sequence
alignment as described previously for other viral proteins
(Naganawa et al., 2008; Oka et al., 2009; Takahata et al., 2017) on
the basis of Shannon’s equation (Shannon, 1997):
H(i) =−
∑
xi
p(xi) log2 p(xi)
(xi = G, A, I, V, ......), (1)
where H(i), p(xi), and i indicate the amino acid entropy score of
a given position, the probability of occurrence of a given amino
acid at the position, and the number of positions, respectively.
AnH(i) score of zero indicates absolute conservation, whereas 4.4
bits for amino acids or 2.0 bits for nucleic acids indicates complete
randomness.
Analysis of Amino Acid Substitutions by
Hamming Distance
We used the Hamming distance to assess the changeability of
the earliest NoV GII.4_2006b variant in Japan. In information
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theory, the Hamming distance between two sequences indicates
the minimum number of “amino acid substitutions” required
to change one sequence into the other. Because the length
of amino acid sequences of the VP1 proteins of the NoV
GII.4_2006b subpopulations were identical (540 amino acid
residues), the Hamming distance measured in this study means
the number of different amino acid residues between the earliest
and subsequently emerged variants in two aligned sequences.
Python was used as the programming language to compute
Hamming distances. Hamming distances between the sequence
in May 2006 (accession number AB447443; earliest GII.4_2006b
sequence in our NoV genome dataset) and the later GII.4_2006b
sequences (n = 249) were computed by creating a sequence that
assigns mismatches and matches at corresponding positions in
the two sequences, and then by counting the numbers of the
mismatches.
Nucleotide Accession Numbers
The DDBJ database accession numbers of the 317 NoV
GII.4 genome sequences used in this study are provided
in Supplementary Table S1 (n = 250, GII.4_2006b) and
Supplementary Table S2 (n= 67, GII.4 non-2006b).
RESULTS
Persistence and Diversification of NoV
GII.4_2006b Genome in Japan between
2006 and 2011
We obtained 317 genome sequences of NoV GII.4 from the
stool specimens collected at 20 sites in Japan between 2006 and
2011 (Figure 1A). Eight distinct lineages of NoV GII.4 were
FIGURE 1 | Persistence and diversification of NoV GII.4_2006b genome in Japan between 2006 and 2011. (A) Geographic locations of the 20 sample
collection sites in Japan (see Supplementary Tables S1, S2 for the seasons and sites of collection). (B) Detection frequency of the GII.4_2006b variants in each
period. NoV GII.4 genome sequences (n = 317) from stool specimens collected at the 20 sites between May 2006 and March 2011 were divided into five groups on
the basis of the collection periods, i.e., 0–11 months (the season 1, n = 41), 12–23 months (the season 2, n = 75), 24–35 months (the season 3, n = 78),
36–47 months (the season 4, n = 76), and 48–58 months (the season 5, n = 47) after the first detection of GII.4 in May 2006 in Japan in this study. Genotypes of the
GII.4 variants were determined with phylogenetic trees of the whole genome sequences as described previously (Motomura et al., 2008, 2010). The detection
frequency of the GII.4_2006b genomes among the total GII.4 genomes in each collection period is shown. (C) Phylogenetic classification of the NoV GII.4 genome
sequences used in this study. The maximum likelihood tree was constructed with the 317 GII.4 genome sequences (about 7.5 kb). The sequence cluster enclosed
by a light-blue oval indicates the GII.4_2006b genomes.
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identified in this period. These lineages include “2004/05” related
to Sakai/04-179/2005/JP cluster, “2006a” related to Yerseke 2006a
cluster, “2006b” related to Den Haag 2006b cluster, “2007a,”
“2007b,” “2008a” related to Apeldoorn317/2007/NL cluster,
“2008b,” and “2009a” related to New Orleans 1805/2009/USA
cluster (Motomura et al., 2008, 2010; Supplementary Tables S1,
S2). Among the newly emerged eight GII.4 lineages, only the
pandemic variant GII.4_2006b had been detected dominantly
and continually throughout Japan (Figure 1B). The GII.4_2006b
represented about 79% (n = 250) of the total GII.4 genomes
detected during the 5 years. Phylogenetic analysis shows that
the GII.4_2006b genome sequences diverged radially from a
few roots (Figure 1C). These data suggest genetic bottlenecks
followed by a rapid genome diversification of GII.4_2006b
between 2006 and 2011.
Diversity of NoV GII.4_2006b ORFs
The GII.4_2006b RNA genome encodes three open reading
frames, ORF1, ORF2, and ORF3 (Figure 2A). ORF1 encodes viral
enzymes and non-structural proteins. ORF2 and ORF3 encodes
structural proteins, VP1 and VP2, respectively. We first examined
whether the sequence diversity is different among the three ORFs
by using the 250 GII.4_2006b genome sequences obtained in
this study. The phylogenetic tree and mean diversity in the
entire sequence population show that the nucleotide diversity was
similar among the three ORFs (Figure 2B). In contrast, a marked
difference was observed in the diversity of amino acid sequences:
the ORF1 and ORF2 amino acid sequences remained significantly
less diversified than that of ORF3 (Figure 2C). The data suggest
the presence of constraints on the amino acid changes of proteins
encoded by ORF1 and ORF2.
Temporal Changes in the Sequence
Diversity of NoV GII.4_2006b
The GII.4_2006b RNA genome encodes eight viral proteins
(Figure 3A). Shannon entropy of amino acid sequences of the
2006b ORF1 in the present genome dataset indicates that the
potential sites for the internal cleavage of the ORF1 precursor
protein were perfectly conserved in amino acid levels [H(i)= 0/0]
for p48/NTPase (Q/G), NTPase/p22 (Q/G), and VPg/Pro (E/A),
FIGURE 2 | Diversity of NoV GII.4_2006b ORFs. (A) Schematic illustration of the locations of the three ORFs in the NoV GII.4_2006b genome. The nucleotide
positions are based on the sequence of the earliest GII.4_2006b in our NoV genome dataset (Supplementary Table S1, Accession No. AB447443). (B,C)
Neighbor-joining trees (Left) and diversity scores (Right) of the sequences of the ORF1, 2, and 3 regions in the 250 NoV GII.4_2006b genomes identified in
Figure 1C. The analyses were done with tools included in the MEGA software suite (Tamura et al., 2011). Nucleotide sequences (B). Amino acid sequences (C).
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FIGURE 3 | Temporal changes in the sequence diversity of NoV GII.4_2006b. (A) Schematic illustration of the locations of the protein-coding regions in the
NoV GII.4_2006b genome. The nucleotide positions are based on the sequence of the earliest GII.4_2006b in our NoV genome dataset (Supplementary Table S1,
Accession No. AB447443). (B) Temporal changes in dissimilarity of nucleotide and amino acid sequences in protein-coding regions of the GII.4_2006b genome. The
250 sequences of the GII.4_2006b genome were divided into five groups on the basis of the collection periods, i.e., 0–11 months (the season 1, n = 41),
12–23 months (the season 2, n = 75), 24–35 months (the season 3, n = 78), 36–47 months (the season 4, n = 76), and 48–58 months (the season 5, n = 47) after
the first detection of GII.4_2006b in May 2006 in Japan in this study. The overall pairwise mean distance between the sequences was calculated for each season
using MEGA software (Tamura et al., 2011). Black and blue circles indicate the mean distances of nucleotide (Nuc) and amino acid (Ami) sequences.
and highly conserved for p22/VPg (E/G) [H(i) = 0.03/0.08] and
Pro/Pol (E/G) [H(i) = 0.03/0.03]. To assess the changeability of
individual viral proteins, we examined temporal changes in the
sequence diversity of the eight protein-coding regions using the
250 GII.4_2006b genomes. The genome sequences were divided
into five groups based on the collected seasons, and the overall
mean distance of the sequences in a season was calculated using
MEGA. The nucleotide mean distance sequentially increased for
the eight protein-coding regions (Figure 3B, Nuc), indicating a
continuous increase in the dissimilarity of every gene segment in
the GII.4_2006b variant population in Japan.
In contrast, the temporal change in amino acid sequence
diversity was very different among the eight proteins (Figure 3B,
Ami). Interestingly, the amino acid mean distance of the
generally hypervariable VP1 protein sequences remained
comparable to that of three viral enzymes (NTPase, Pro, Pol)
for 5 years, with the mean distance remaining at less than
0.01 with small variances (Figure 3B, Upper). After the 3rd
epidemic season, the VP1 amino acid distance even decreased.
Meanwhile, the amino acid mean distances of the p22 and VP2
proteins sharply increased in parallel with an increase in the
nucleotide distances (Figure 3B, p22 and VP2), suggesting the
continuous diversification of these proteins in association with
nucleotide diversification. The mean amino acid distance for the
p48 protein increased with time yet less extensively than those
for the p22 and VP2 proteins (Figure 3B, p48). The mean amino
acid distance for the VPg protein stayed at relatively low levels
with large variances (Figure 3B, VPg). In sum, these data suggest
the presence of strong constraints on amino acid changes in
the capsid protein VP1 and enzymes (NTPase, Pro, Pol) of the
GII.4_2006b under the diversification of nucleotide sequences.
Long-term Circulation of the NoV
GII.4_2006b Subgroup Carrying the
Identical Capsid Protein VP1
We identified a GII.4_2006b subpopulation (n = 23) whose
nucleotide sequences differed from each other, yet encoded
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FIGURE 4 | Long-term circulation of the NoV GII.4_2006b subgroup carrying the identical capsid protein VP1. (A) Identification of a GII.4_2006b genome
subpopulation group 1 that encodes the identical VP1s in distinct genetic backbones. Nucleotide (Upper) and deduced amino acid (Lower) sequences of the group
1 genomes (n = 23) were aligned using MAFFT software (Katoh et al., 2009), and Shannon entropies at individual positions were calculated as described previously
(Naganawa et al., 2008; Oka et al., 2009; Takahata et al., 2017). The distribution of Shannon entropy scores in the GII.4_2006b genome is shown. (B) Detection
frequency of the group 1 genomes in five seasons between 2006 and 2011 in Japan. (C) Neighbor-joining tree of the GII.4_2006b VP1 nucleotide sequences (1620
nucleotides). Colored circles indicate the group 1 sequences. (D) P domain dimer model of the GII.4_2006b VP1 protein was constructed as described (Motomura
et al., 2008, 2010). Blue residues indicate the GII.4_2006b-specific amino acid substitutions at potential epitopes in the P2 subdomain of the GII.4 VP1 (Lindesmith
et al., 2012b).
exactly the same VP1 amino acid sequences (Figure 4A). The
members of this population, tentatively termed group 1, were
detected at distantly located 11 sample collection sites in Japan
during the study period (Supplementary Table S1 and Figure
S1). They emerged in the second epidemic season in 2007 and
continuously circulated without no changes in the VP1 amino
acid residues, representing about 6–13% of the GII.4_2006b
genomes in each season (Figure 4B). The group 1 genomes
continuously accumulated nucleotide substitutions in the VP1-
coding region (Figure 4C), but only synonymous substitutions
(Figure 4A). The GII.4_2006b variants at the onset of epidemics
generally had 10 substitutions at the potential epitopes A, B,
D, and E (Lindesmith et al., 2012a) of the VP1 P2 subdomain
(P294A, T296S, T298N, A368S, D372E, M333V, R382K, S394T,
D407S, and T412N), as compared with the VP1 sequence of
the past epidemic variant in 2004/2005 in Japan (Sakai/04-
179/2005/JP: accession number BAE98194) (Figure 4D). The
group 1 VP1 protein had an additional substitution (S393G) on
the epitope D.
Temporal Change in Hamming Distance
for the NoV GII.4_2006b Capsid Protein
VP1
The NoV VP1 protein has an architecture similar to that
of the VP1 proteins of other single-stranded RNA viruses
(Prasad et al., 1994, 1999; Figure 5A). The S domain is highly
conserved, whereas the P2 domain is hypervariable among GII.4
variants. To assess the changeability of the P2 domain of the
GII.4_2006b, we examined the temporal accumulations of amino
acid substitutions in the S, P1, and P2 regions of the GII.4_2006b
VP1 using the Hamming distance between the earliest and
subsequent VP1 variants. As the earliest VP1 variant of the
GII.4_2006b, we used a sequence from a May 2006 sample, which
was collected in spring about 5 months before the onset of the
nationwide epidemics of the GII.4_2006b in October of 2006 in
Japan (Motomura et al., 2008).
For the S domain, the Hamming distances of the variants in
given seasons were at a constant peak of 0 for 5 years (Figure 5B,
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FIGURE 5 | Temporal change in Hamming distance for the NoV GII.4_2006b capsid protein VP1. (A) Schematic illustration of the locations of the S, P1, and
P2 domains in the ORF2 (Left) and the VP1 3-D model (Right) of the NoV GII.4_2006b. (B) Temporal changes in the Hamming distance. A GII.4_2006b genome from
a stool specimen collected in May 2006 in Toyama (accession number AB447443) was the oldest in our GII.4_2006b genome dataset. The sequence was used to
calculate the Hamming distance between the earliest and subsequent VP1 variants emerged between October 2006 and March 2011 in Japan. The distributions of
the Hamming distances for each season are shown for the S, P1, and P2 domains of the VP1 protein. Temporal changes in the Hamming distance are also shown
for the VP2 protein (Lower right).
VP1 Shell). The data suggest that the GII.4_2006b variants having
amino acid substitutions in the S domain were mostly cleared
during epidemics. For the P1 and P2 subdomains, the peaks
of Hamming distances were fixed at 1 and 3 after the second
and first epidemic seasons, respectively (Figure 5B, VP1 P1 and
P2). The data indicate that most of the GII.4_2006b variants
in the early epidemics had a few amino acid substitutions in
the P domain but they could not accumulate more mutations
after the second epidemic season. Thus the P domain was more
variable than the S domain in the GII.4_2006b variants, as
has generally been documented for other NoVs. However, the
accumulation of amino acid substitutions was strictly constrained
in the P domain of the GII.4_2006b variants during epidemics.
In contrast, the Hamming distances of VP2, a minor structural
protein in virion (Glass et al., 2000), continuously increased and
showed no evidence of fixation of the peak distance during the
study period (Figure 5B, VP2).
DISCUSSION
In this report, we studied molecular evolution of the NoV
capsid protein of a pandemic lineage, GII.4_2006b. This NoV
subpopulation predominated over other coexisting NoV GII.4
subpopulations between the 2006 and 2011 in Japan (Figure 1).
Notably, the amino acid sequences of variable VP1 protein
of the GII.4_2006b populations remained as homogeneous as
that of the viral enzymes for the 5 years under an increase
in nucleotide diversity (Figures 2, 3). Even the GII.4_2006b
population possessing the identical amino acid sequence in
the VP1 protein had persisted in the study period (Figure 4).
Even the hypervariable antigenic P2 subdomain of the VP1
protein had resisted sequential accumulations of amino acid
substitutions (Figure 5). These results suggest the presence
of strong evolutionary constraints on the VP1 protein of
the NoV pandemic strain. The finding has implications for
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our understanding of molecular evolution, mechanisms of the
periodic shifts in the pandemic NoV GII.4 strains, and control
of the NoV GII.4 pandemic strain.
First, the finding has implications for understanding fitness
landscape and evolution of the VP1 protein of NoV GII.4
pandemic strain. The strong constraints on changes imply that
the VP1 protein and enzymes of the GII.4_2006b variants had
already gained near maximal levels of fitness benefits in humans
around the onset of the outbreaks and that new mutations
in the VP1 protein were mostly cleared from the GII.4_2006b
population, probably due to a reduction in the viral fitness
for the spread in humans. In order to predominate over other
coexisting GII.4 variants, the pandemic variant should have the
VP1 structure that confers the best ability to evade preexisting
herd immunity against NoV at that time, while also having
affinity to bind to receptor(s) on human cells. Because the
antigenic sites are located near the receptor-binding site, new
antigenic mutations always have the risk to attenuate VP1 protein
function and thereby to cause reduction in the viral replication
fitness in humans. Thus, it is possible that the VP1 protein of the
pandemic strain had remained conserved in human populations
primarily by the necessity to maintain advantageous physical
property of the VP1 protein for immune evasion and infectivity
simultaneously.
Secondary, the finding has implications in the periodic shifts
of the pandemic NoV GII.4 strains. Provided that the VP1 protein
sequence of a given pandemic variant remained conserved
following the onset of epidemics as seen in the GII.4_2006b, the
human herd immunity against the VP1 protein would become
increasingly more effective in association with the spread of the
virus in humans. Consequently, niche for the pandemic variant in
humans would be reduced, and the pandemic variant eventually
be replaced by an alternative variant that has the fittest capsid
structure under human herd immunity at that time. Consistently,
the numbers of reported NoV infection cases in Japan had
decreased annually since the late 2007, and the GII.4_2006b was
replaced by a new global pandemic strain GII.4_Sydney 2012 in
the 2013/2014 season, as reported in other countries (van Beek
et al., 2013; Eden et al., 2014).
Finally, the finding has implications in the control of
NoV pandemic strains. Although development of vaccines and
antiviral agents are of special importance to reduce damages from
the NoV infections, structural variations in the viral proteins
can be problematic. In this regard, the present study suggests
the presence of strong constraints on changes in capsid protein
and enzymes of a NoV GII.4 pandemic variant on the course of
5-year persistence across Japan. The finding provides a rationale
for developing vaccines and antiviral agents against a pandemic
strain. A basic premise of the control is that the sequences
of the VP1 protein and viral enzymes of a given pandemic
variant remain highly homogeneous after the onset of pandemic.
Therefore, it is important to further accumulate information
on the evolution of newly emerged pandemic strains to clarify
whether present observations of the amino acid conservation
in the VP1 and viral enzymes can be extended to other GII.4
pandemic variants. In parallel, it would be important to study
genetic diversity of NoV in nature in order to develop systems
to predict a new pandemic variant in advance.
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